Viracta Therapeutics gets $50 million refinancing credit facility

By Marisa Wong

Los Angeles, Nov. 5 – Viracta Therapeutics, Inc. entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance LLC for up to $50 million, according to a press release.

In connection with the new credit facility, Viracta terminated its prior $15 million loan and security agreement, and the existing $5 million debt balance was refinanced.

Under this new $50 million credit facility, the remaining $45 million is available in two additional tranches of $20 million and $25 million.

The company is under no obligation to draw funds in the future.

Viracta is a San Diego-based oncology company primarily focused on targeting virus-associated malignancies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.